CTOs on the Move

Celmatix

www.celmatix.com

 
Founded in 2009, Celmatix is a personalized medicine company focused on fertility and women’s health. Our technology-enabled products empower people, through better data, to dramatically improve their chances of conceiving.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.celmatix.com
  • 14 Wall Street Suite 16D
    New York, NY USA 10005
  • Phone: 646.389.0245

Executives

Name Title Contact Details
Mark Adams
Chief Information Officer Profile

Similar Companies

Novus Therapeutics

Novus Therapeutics, Inc. (NASDAQ: NVUS) is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease.

Affinivax

Affinivax is a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines designed to induce a broad and robust protective immune response to both disease-relevant polysaccharides and disease-relevant proteins in a single vaccine. Affinivax designs each of its vaccine candidates to optimize the protective immune response to one or both of these antigens utilizing the distinctive plug-and-play nature of its proprietary MAPS™ technology platform, presenting the potential opportunity to make a significant step forward in addressing major healthcare challenges posed by novel and resistant infectious diseases. Affinivax was founded in 2014 with a seed investment from the Bill & Melinda Gates Foundation and an exclusive license to the MAPS technology from Boston Children`s Hospital.

Hydra Biosciences

Hydra Biosciences is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Florida Hospital Orlando

Florida Hospital Orlando is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inceptor Bio

Inceptor Bio is developing multiple next-generation cell therapy platforms to cure difficult-to-treat cancers with a focus on novel mechanisms to enhance immune cell performance in the tumor microenvironment.